APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

IBS-C Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

IBS-C Drugs Industry Research Report 2026

Report ID 174001260520 December 2025150 pages

Choose your research edition.

Industry ResearchIBS-C Drugs Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal IBS-C Drugs Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal IBS-C Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IBS-C Drugs Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal IBS-C Drugs Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global IBS-C Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for IBS-C Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for IBS-C Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for IBS-C Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of IBS-C Drugs include Abbott Laboratories, Actavis Nordic A/S, Albireo Pharma Inc, Ardelyx, Inc, Astellas Pharmaceuticals, Bama-Geve, SLU, Catalent Pharmaceuticals Solutions, Ferring BV and Ironwood Pharmaceuticals, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global IBS-C Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

IBS-C Drugs Market by Company

Abbott Laboratories

Actavis Nordic A/S

Albireo Pharma Inc

Ardelyx, Inc

Astellas Pharmaceuticals

Bama-Geve, SLU

Catalent Pharmaceuticals Solutions

Ferring BV

Ironwood Pharmaceuticals, Inc

Norgine B.V

Novartis Pharma Ag

Ono Pharmaceutical Co., Ltd

Prometheus Laboratories Inc

Salix Pharmaceuticals Ltd

Sucampo Pharmaceuticals

Synergy Pharmaceuticals

Synthetic Biologics, Inc

Teva Pharmaceutical Industries

The Menarini Group

Yuhan Corp

Astrazeneca Plc

Nestle

IBS-C Drugs Segment by Type

Stimulant Laxatives

Linaclotide

Lubiprostone

Osmotic Laxatives

Others

IBS-C Drugs Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

IBS-C Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IBS-C Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IBS-C Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IBS-C Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of IBS-C Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of IBS-C Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of IBS-C Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global IBS-C Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global IBS-C Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global IBS-C Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global IBS-C Drugs Revenue of Manufacturers (2021-2026) Table 9. Global IBS-C Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market IBS-C Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global IBS-C Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of IBS-C Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of IBS-C Drugs, Product Type & Application Table 14. Global IBS-C Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global IBS-C Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Abbott Laboratories Company Information Table 19. Abbott Laboratories Business Overview Table 20. Abbott Laboratories IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Abbott Laboratories IBS-C Drugs Product Portfolio Table 22. Abbott Laboratories Recent Developments Table 23. Actavis Nordic A/S Company Information Table 24. Actavis Nordic A/S Business Overview Table 25. Actavis Nordic A/S IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Actavis Nordic A/S IBS-C Drugs Product Portfolio Table 27. Actavis Nordic A/S Recent Developments Table 28. Albireo Pharma Inc Company Information Table 29. Albireo Pharma Inc Business Overview Table 30. Albireo Pharma Inc IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Albireo Pharma Inc IBS-C Drugs Product Portfolio Table 32. Albireo Pharma Inc Recent Developments Table 33. Ardelyx, Inc Company Information Table 34. Ardelyx, Inc Business Overview Table 35. Ardelyx, Inc IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Ardelyx, Inc IBS-C Drugs Product Portfolio Table 37. Ardelyx, Inc Recent Developments Table 38. Astellas Pharmaceuticals Company Information Table 39. Astellas Pharmaceuticals Business Overview Table 40. Astellas Pharmaceuticals IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Astellas Pharmaceuticals IBS-C Drugs Product Portfolio Table 42. Astellas Pharmaceuticals Recent Developments Table 43. Bama-Geve, SLU Company Information Table 44. Bama-Geve, SLU Business Overview Table 45. Bama-Geve, SLU IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Bama-Geve, SLU IBS-C Drugs Product Portfolio Table 47. Bama-Geve, SLU Recent Developments Table 48. Catalent Pharmaceuticals Solutions Company Information Table 49. Catalent Pharmaceuticals Solutions Business Overview Table 50. Catalent Pharmaceuticals Solutions IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Catalent Pharmaceuticals Solutions IBS-C Drugs Product Portfolio Table 52. Catalent Pharmaceuticals Solutions Recent Developments Table 53. Ferring BV Company Information Table 54. Ferring BV Business Overview Table 55. Ferring BV IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Ferring BV IBS-C Drugs Product Portfolio Table 57. Ferring BV Recent Developments Table 58. Ironwood Pharmaceuticals, Inc Company Information Table 59. Ironwood Pharmaceuticals, Inc Business Overview Table 60. Ironwood Pharmaceuticals, Inc IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Ironwood Pharmaceuticals, Inc IBS-C Drugs Product Portfolio Table 62. Ironwood Pharmaceuticals, Inc Recent Developments Table 63. Norgine B.V Company Information Table 64. Norgine B.V Business Overview Table 65. Norgine B.V IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Norgine B.V IBS-C Drugs Product Portfolio Table 67. Norgine B.V Recent Developments Table 68. Novartis Pharma Ag Company Information Table 69. Novartis Pharma Ag Business Overview Table 70. Novartis Pharma Ag IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Novartis Pharma Ag IBS-C Drugs Product Portfolio Table 72. Novartis Pharma Ag Recent Developments Table 73. Ono Pharmaceutical Co., Ltd Company Information Table 74. Ono Pharmaceutical Co., Ltd Business Overview Table 75. Ono Pharmaceutical Co., Ltd IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Ono Pharmaceutical Co., Ltd IBS-C Drugs Product Portfolio Table 77. Ono Pharmaceutical Co., Ltd Recent Developments Table 78. Prometheus Laboratories Inc Company Information Table 79. Prometheus Laboratories Inc Business Overview Table 80. Prometheus Laboratories Inc IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Prometheus Laboratories Inc IBS-C Drugs Product Portfolio Table 82. Prometheus Laboratories Inc Recent Developments Table 83. Salix Pharmaceuticals Ltd Company Information Table 84. Salix Pharmaceuticals Ltd Business Overview Table 85. Salix Pharmaceuticals Ltd IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Salix Pharmaceuticals Ltd IBS-C Drugs Product Portfolio Table 87. Salix Pharmaceuticals Ltd Recent Developments Table 88. Sucampo Pharmaceuticals Company Information Table 89. Sucampo Pharmaceuticals Business Overview Table 90. Sucampo Pharmaceuticals IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Sucampo Pharmaceuticals IBS-C Drugs Product Portfolio Table 92. Sucampo Pharmaceuticals Recent Developments Table 93. Synergy Pharmaceuticals Company Information Table 94. Synergy Pharmaceuticals Business Overview Table 95. Synergy Pharmaceuticals IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Synergy Pharmaceuticals IBS-C Drugs Product Portfolio Table 97. Synergy Pharmaceuticals Recent Developments Table 98. Synthetic Biologics, Inc Company Information Table 99. Synthetic Biologics, Inc Business Overview Table 100. Synthetic Biologics, Inc IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Synthetic Biologics, Inc IBS-C Drugs Product Portfolio Table 102. Synthetic Biologics, Inc Recent Developments Table 103. Teva Pharmaceutical Industries Company Information Table 104. Teva Pharmaceutical Industries Business Overview Table 105. Teva Pharmaceutical Industries IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Teva Pharmaceutical Industries IBS-C Drugs Product Portfolio Table 107. Teva Pharmaceutical Industries Recent Developments Table 108. The Menarini Group Company Information Table 109. The Menarini Group Business Overview Table 110. The Menarini Group IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. The Menarini Group IBS-C Drugs Product Portfolio Table 112. The Menarini Group Recent Developments Table 113. Yuhan Corp Company Information Table 114. Yuhan Corp Business Overview Table 115. Yuhan Corp IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Yuhan Corp IBS-C Drugs Product Portfolio Table 117. Yuhan Corp Recent Developments Table 118. Astrazeneca Plc Company Information Table 119. Astrazeneca Plc Business Overview Table 120. Astrazeneca Plc IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Astrazeneca Plc IBS-C Drugs Product Portfolio Table 122. Astrazeneca Plc Recent Developments Table 123. Nestle Company Information Table 124. Nestle Business Overview Table 125. Nestle IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Nestle IBS-C Drugs Product Portfolio Table 127. Nestle Recent Developments Table 128. Global IBS-C Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 129. Global IBS-C Drugs Sales by Region (2021-2026) & (K Units) Table 130. Global IBS-C Drugs Sales Market Share by Region (2021-2026) Table 131. Global IBS-C Drugs Sales by Region (2027-2032) & (K Units) Table 132. Global IBS-C Drugs Sales Market Share by Region (2027-2032) Table 133. Global IBS-C Drugs Revenue by Region (2021-2026) & (US$ Million) Table 134. Global IBS-C Drugs Revenue Market Share by Region (2021-2026) Table 135. Global IBS-C Drugs Revenue by Region (2027-2032) & (US$ Million) Table 136. Global IBS-C Drugs Revenue Market Share by Region (2027-2032) Table 137. North America IBS-C Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. North America IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 139. North America IBS-C Drugs Sales by Country (2027-2032) & (K Units) Table 140. North America IBS-C Drugs Revenue by Country (2021-2026) & (US$ Million) Table 141. North America IBS-C Drugs Revenue by Country (2027-2032) & (US$ Million) Table 142. Europe IBS-C Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Europe IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 144. Europe IBS-C Drugs Sales by Country (2027-2032) & (K Units) Table 145. Europe IBS-C Drugs Revenue by Country (2021-2026) & (US$ Million) Table 146. Europe IBS-C Drugs Revenue by Country (2027-2032) & (US$ Million) Table 147. Asia Pacific IBS-C Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. Asia Pacific IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 149. Asia Pacific IBS-C Drugs Sales by Country (2027-2032) & (K Units) Table 150. Asia Pacific IBS-C Drugs Revenue by Country (2021-2026) & (US$ Million) Table 151. Asia Pacific IBS-C Drugs Revenue by Country (2027-2032) & (US$ Million) Table 152. South America IBS-C Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. South America IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 154. South America IBS-C Drugs Sales by Country (2027-2032) & (K Units) Table 155. South America IBS-C Drugs Revenue by Country (2021-2026) & (US$ Million) Table 156. South America IBS-C Drugs Revenue by Country (2027-2032) & (US$ Million) Table 157. Middle East and Africa IBS-C Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 158. Middle East and Africa IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 159. Middle East and Africa IBS-C Drugs Sales by Country (2027-2032) & (K Units) Table 160. Middle East and Africa IBS-C Drugs Revenue by Country (2021-2026) & (US$ Million) Table 161. Middle East and Africa IBS-C Drugs Revenue by Country (2027-2032) & (US$ Million) Table 162. Global IBS-C Drugs Sales by Type (2021-2026) & (K Units) Table 163. Global IBS-C Drugs Sales by Type (2027-2032) & (K Units) Table 164. Global IBS-C Drugs Sales Market Share by Type (2021-2026) Table 165. Global IBS-C Drugs Sales Market Share by Type (2027-2032) Table 166. Global IBS-C Drugs Revenue by Type (2021-2026) & (US$ Million) Table 167. Global IBS-C Drugs Revenue by Type (2027-2032) & (US$ Million) Table 168. Global IBS-C Drugs Revenue Market Share by Type (2021-2026) Table 169. Global IBS-C Drugs Revenue Market Share by Type (2027-2032) Table 170. Global IBS-C Drugs Price by Type (2021-2026) & (US$/Unit) Table 171. Global IBS-C Drugs Price by Type (2027-2032) & (US$/Unit) Table 172. Global IBS-C Drugs Sales by Application (2021-2026) & (K Units) Table 173. Global IBS-C Drugs Sales by Application (2027-2032) & (K Units) Table 174. Global IBS-C Drugs Sales Market Share by Application (2021-2026) Table 175. Global IBS-C Drugs Sales Market Share by Application (2027-2032) Table 176. Global IBS-C Drugs Revenue by Application (2021-2026) & (US$ Million) Table 177. Global IBS-C Drugs Revenue by Application (2027-2032) & (US$ Million) Table 178. Global IBS-C Drugs Revenue Market Share by Application (2021-2026) Table 179. Global IBS-C Drugs Revenue Market Share by Application (2027-2032) Table 180. Global IBS-C Drugs Price by Application (2021-2026) & (US$/Unit) Table 181. Global IBS-C Drugs Price by Application (2027-2032) & (US$/Unit) Table 182. Key Raw Materials Table 183. Raw Materials Key Suppliers Table 184. IBS-C Drugs Distributors List Table 185. IBS-C Drugs Customers List Table 186. IBS-C Drugs Industry Trends Table 187. IBS-C Drugs Industry Drivers Table 188. IBS-C Drugs Industry Restraints Table 189. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. IBS-C Drugs Product Image Figure 5. Global IBS-C Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global IBS-C Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global IBS-C Drugs Sales (2021-2032) & (K Units) Figure 8. Global IBS-C Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. Stimulant Laxatives Product Image Figure 10. Linaclotide Product Image Figure 11. Lubiprostone Product Image Figure 12. Osmotic Laxatives Product Image Figure 13. Others Product Image Figure 14. Hospital Pharmacies Product Image Figure 15. Online Pharmacies Product Image Figure 16. Retail Pharmacies Product Image Figure 17. Global IBS-C Drugs Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of IBS-C Drugs, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 IBS-C Drugs Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global IBS-C Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global IBS-C Drugs Sales by Region in 2025 Figure 23. Global IBS-C Drugs Revenue by Region in 2025 Figure 24. North America IBS-C Drugs Market Size by Country in 2025 Figure 25. North America IBS-C Drugs Sales Market Share by Country (2021-2032) Figure 26. North America IBS-C Drugs Revenue Market Share by Country (2021-2032) Figure 27. United States IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe IBS-C Drugs Market Size by Country in 2025 Figure 30. Europe IBS-C Drugs Sales Market Share by Country (2021-2032) Figure 31. Europe IBS-C Drugs Revenue Market Share by Country (2021-2032) Figure 32. Germany IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Nordic Countries IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Asia Pacific IBS-C Drugs Market Size by Country in 2025 Figure 39. Asia Pacific IBS-C Drugs Sales Market Share by Country (2021-2032) Figure 40. Asia Pacific IBS-C Drugs Revenue Market Share by Country (2021-2032) Figure 41. China IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Japan IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. South Korea IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. India IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Australia IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. China Taiwan IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Southeast Asia IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South America IBS-C Drugs Market Size by Country in 2025 Figure 50. South America IBS-C Drugs Sales Market Share by Country (2021-2032) Figure 51. South America IBS-C Drugs Revenue Market Share by Country (2021-2032) Figure 52. Mexico IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Brazil IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Argentina IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Colombia IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Middle East and Africa IBS-C Drugs Market Size by Country in 2025 Figure 57. Middle East and Africa IBS-C Drugs Sales Market Share by Country (2021-2032) Figure 58. Middle East and Africa IBS-C Drugs Revenue Market Share by Country (2021-2032) Figure 59. Turkey IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Saudi Arabia IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. UAE IBS-C Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Global IBS-C Drugs Sales Market Share by Type (2021-2032) Figure 63. Global IBS-C Drugs Revenue Market Share by Type (2021-2032) Figure 64. Global IBS-C Drugs Price (US$/Unit) by Type (2021-2032) Figure 65. Global IBS-C Drugs Sales Market Share by Application (2021-2032) Figure 66. Global IBS-C Drugs Revenue Market Share by Application (2021-2032) Figure 67. Global IBS-C Drugs Price (US$/Unit) by Application (2021-2032) Figure 68. IBS-C Drugs Value Chain Figure 69. IBS-C Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. IBS-C Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Stimulant Laxatives
  • Linaclotide
  • Lubiprostone
  • Osmotic Laxatives
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Abbott Laboratories
  • Actavis Nordic A/S
  • Albireo Pharma Inc
  • Ardelyx, Inc
  • Astellas Pharmaceuticals
  • Bama-Geve, SLU
  • Catalent Pharmaceuticals Solutions
  • Ferring BV
  • Ironwood Pharmaceuticals, Inc
  • Norgine B.V
  • Novartis Pharma Ag
  • Ono Pharmaceutical Co., Ltd
  • Prometheus Laboratories Inc
  • Salix Pharmaceuticals Ltd
  • Sucampo Pharmaceuticals
  • Synergy Pharmaceuticals
  • Synthetic Biologics, Inc
  • Teva Pharmaceutical Industries
  • The Menarini Group
  • Yuhan Corp
  • Astrazeneca Plc
  • Nestle

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global IBS-C Drugs Market Size (2021-2032)
  4. 2.2.2 Global IBS-C Drugs Sales (2021-2032)
  5. 2.2.3 Global IBS-C Drugs Market Average Price (2021-2032)
  6. 2.3 IBS-C Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Stimulant Laxatives
  9. 2.3.3 Linaclotide
  10. 2.3.4 Lubiprostone
  11. 2.3.5 Osmotic Laxatives
  12. 2.3.6 Others
  13. 2.4 IBS-C Drugs by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Hospital Pharmacies
  16. 2.4.3 Online Pharmacies
  17. 2.4.4 Retail Pharmacies
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global IBS-C Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global IBS-C Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global IBS-C Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global IBS-C Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global IBS-C Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of IBS-C Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of IBS-C Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of IBS-C Drugs, Established Date
  9. 3.9 Global IBS-C Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Abbott Laboratories
  2. 4.1.1 Abbott Laboratories Company Information
  3. 4.1.2 Abbott Laboratories Business Overview
  4. 4.1.3 Abbott Laboratories IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Abbott Laboratories IBS-C Drugs Product Portfolio
  6. 4.1.5 Abbott Laboratories Recent Developments
  7. 4.2 Actavis Nordic A/S
  8. 4.2.1 Actavis Nordic A/S Company Information
  9. 4.2.2 Actavis Nordic A/S Business Overview
  10. 4.2.3 Actavis Nordic A/S IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Actavis Nordic A/S IBS-C Drugs Product Portfolio
  12. 4.2.5 Actavis Nordic A/S Recent Developments
  13. 4.3 Albireo Pharma Inc
  14. 4.3.1 Albireo Pharma Inc Company Information
  15. 4.3.2 Albireo Pharma Inc Business Overview
  16. 4.3.3 Albireo Pharma Inc IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Albireo Pharma Inc IBS-C Drugs Product Portfolio
  18. 4.3.5 Albireo Pharma Inc Recent Developments
  19. 4.4 Ardelyx, Inc
  20. 4.4.1 Ardelyx, Inc Company Information
  21. 4.4.2 Ardelyx, Inc Business Overview
  22. 4.4.3 Ardelyx, Inc IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Ardelyx, Inc IBS-C Drugs Product Portfolio
  24. 4.4.5 Ardelyx, Inc Recent Developments
  25. 4.5 Astellas Pharmaceuticals
  26. 4.5.1 Astellas Pharmaceuticals Company Information
  27. 4.5.2 Astellas Pharmaceuticals Business Overview
  28. 4.5.3 Astellas Pharmaceuticals IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Astellas Pharmaceuticals IBS-C Drugs Product Portfolio
  30. 4.5.5 Astellas Pharmaceuticals Recent Developments
  31. 4.6 Bama-Geve, SLU
  32. 4.6.1 Bama-Geve, SLU Company Information
  33. 4.6.2 Bama-Geve, SLU Business Overview
  34. 4.6.3 Bama-Geve, SLU IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Bama-Geve, SLU IBS-C Drugs Product Portfolio
  36. 4.6.5 Bama-Geve, SLU Recent Developments
  37. 4.7 Catalent Pharmaceuticals Solutions
  38. 4.7.1 Catalent Pharmaceuticals Solutions Company Information
  39. 4.7.2 Catalent Pharmaceuticals Solutions Business Overview
  40. 4.7.3 Catalent Pharmaceuticals Solutions IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Catalent Pharmaceuticals Solutions IBS-C Drugs Product Portfolio
  42. 4.7.5 Catalent Pharmaceuticals Solutions Recent Developments
  43. 4.8 Ferring BV
  44. 4.8.1 Ferring BV Company Information
  45. 4.8.2 Ferring BV Business Overview
  46. 4.8.3 Ferring BV IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Ferring BV IBS-C Drugs Product Portfolio
  48. 4.8.5 Ferring BV Recent Developments
  49. 4.9 Ironwood Pharmaceuticals, Inc
  50. 4.9.1 Ironwood Pharmaceuticals, Inc Company Information
  51. 4.9.2 Ironwood Pharmaceuticals, Inc Business Overview
  52. 4.9.3 Ironwood Pharmaceuticals, Inc IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Ironwood Pharmaceuticals, Inc IBS-C Drugs Product Portfolio
  54. 4.9.5 Ironwood Pharmaceuticals, Inc Recent Developments
  55. 4.10 Norgine B.V
  56. 4.10.1 Norgine B.V Company Information
  57. 4.10.2 Norgine B.V Business Overview
  58. 4.10.3 Norgine B.V IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Norgine B.V IBS-C Drugs Product Portfolio
  60. 4.10.5 Norgine B.V Recent Developments
  61. 4.11 Novartis Pharma Ag
  62. 4.11.1 Novartis Pharma Ag Company Information
  63. 4.11.2 Novartis Pharma Ag Business Overview
  64. 4.11.3 Novartis Pharma Ag IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Novartis Pharma Ag IBS-C Drugs Product Portfolio
  66. 4.11.5 Novartis Pharma Ag Recent Developments
  67. 4.12 Ono Pharmaceutical Co., Ltd
  68. 4.12.1 Ono Pharmaceutical Co., Ltd Company Information
  69. 4.12.2 Ono Pharmaceutical Co., Ltd Business Overview
  70. 4.12.3 Ono Pharmaceutical Co., Ltd IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Ono Pharmaceutical Co., Ltd IBS-C Drugs Product Portfolio
  72. 4.12.5 Ono Pharmaceutical Co., Ltd Recent Developments
  73. 4.13 Prometheus Laboratories Inc
  74. 4.13.1 Prometheus Laboratories Inc Company Information
  75. 4.13.2 Prometheus Laboratories Inc Business Overview
  76. 4.13.3 Prometheus Laboratories Inc IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Prometheus Laboratories Inc IBS-C Drugs Product Portfolio
  78. 4.13.5 Prometheus Laboratories Inc Recent Developments
  79. 4.14 Salix Pharmaceuticals Ltd
  80. 4.14.1 Salix Pharmaceuticals Ltd Company Information
  81. 4.14.2 Salix Pharmaceuticals Ltd Business Overview
  82. 4.14.3 Salix Pharmaceuticals Ltd IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Salix Pharmaceuticals Ltd IBS-C Drugs Product Portfolio
  84. 4.14.5 Salix Pharmaceuticals Ltd Recent Developments
  85. 4.15 Sucampo Pharmaceuticals
  86. 4.15.1 Sucampo Pharmaceuticals Company Information
  87. 4.15.2 Sucampo Pharmaceuticals Business Overview
  88. 4.15.3 Sucampo Pharmaceuticals IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Sucampo Pharmaceuticals IBS-C Drugs Product Portfolio
  90. 4.15.5 Sucampo Pharmaceuticals Recent Developments
  91. 4.16 Synergy Pharmaceuticals
  92. 4.16.1 Synergy Pharmaceuticals Company Information
  93. 4.16.2 Synergy Pharmaceuticals Business Overview
  94. 4.16.3 Synergy Pharmaceuticals IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Synergy Pharmaceuticals IBS-C Drugs Product Portfolio
  96. 4.16.5 Synergy Pharmaceuticals Recent Developments
  97. 4.17 Synthetic Biologics, Inc
  98. 4.17.1 Synthetic Biologics, Inc Company Information
  99. 4.17.2 Synthetic Biologics, Inc Business Overview
  100. 4.17.3 Synthetic Biologics, Inc IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Synthetic Biologics, Inc IBS-C Drugs Product Portfolio
  102. 4.17.5 Synthetic Biologics, Inc Recent Developments
  103. 4.18 Teva Pharmaceutical Industries
  104. 4.18.1 Teva Pharmaceutical Industries Company Information
  105. 4.18.2 Teva Pharmaceutical Industries Business Overview
  106. 4.18.3 Teva Pharmaceutical Industries IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Teva Pharmaceutical Industries IBS-C Drugs Product Portfolio
  108. 4.18.5 Teva Pharmaceutical Industries Recent Developments
  109. 4.19 The Menarini Group
  110. 4.19.1 The Menarini Group Company Information
  111. 4.19.2 The Menarini Group Business Overview
  112. 4.19.3 The Menarini Group IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 The Menarini Group IBS-C Drugs Product Portfolio
  114. 4.19.5 The Menarini Group Recent Developments
  115. 4.20 Yuhan Corp
  116. 4.20.1 Yuhan Corp Company Information
  117. 4.20.2 Yuhan Corp Business Overview
  118. 4.20.3 Yuhan Corp IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Yuhan Corp IBS-C Drugs Product Portfolio
  120. 4.20.5 Yuhan Corp Recent Developments
  121. 4.21 Astrazeneca Plc
  122. 4.21.1 Astrazeneca Plc Company Information
  123. 4.21.2 Astrazeneca Plc Business Overview
  124. 4.21.3 Astrazeneca Plc IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Astrazeneca Plc IBS-C Drugs Product Portfolio
  126. 4.21.5 Astrazeneca Plc Recent Developments
  127. 4.22 Nestle
  128. 4.22.1 Nestle Company Information
  129. 4.22.2 Nestle Business Overview
  130. 4.22.3 Nestle IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Nestle IBS-C Drugs Product Portfolio
  132. 4.22.5 Nestle Recent Developments
5 Global IBS-C Drugs Market Scenario by Region
  1. 5.1 Global IBS-C Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global IBS-C Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global IBS-C Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global IBS-C Drugs Sales by Region: 2027-2032
  5. 5.3 Global IBS-C Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global IBS-C Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global IBS-C Drugs Revenue by Region: 2027-2032
  8. 5.4 North America IBS-C Drugs Market Facts & Figures by Country
  9. 5.4.1 North America IBS-C Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America IBS-C Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America IBS-C Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe IBS-C Drugs Market Facts & Figures by Country
  15. 5.5.1 Europe IBS-C Drugs Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe IBS-C Drugs Sales by Country (2021-2032)
  17. 5.5.3 Europe IBS-C Drugs Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.5.9 Nordic Countries
  24. 5.6 Asia Pacific IBS-C Drugs Market Facts & Figures by Country
  25. 5.6.1 Asia Pacific IBS-C Drugs Market Size by Country: 2021 VS 2025 VS 2032
  26. 5.6.2 Asia Pacific IBS-C Drugs Sales by Country (2021-2032)
  27. 5.6.3 Asia Pacific IBS-C Drugs Revenue by Country (2021-2032)
  28. 5.6.4 China
  29. 5.6.5 Japan
  30. 5.6.6 South Korea
  31. 5.6.7 India
  32. 5.6.8 Australia
  33. 5.6.9 China Taiwan
  34. 5.6.10 Southeast Asia
  35. 5.7 South America IBS-C Drugs Market Facts & Figures by Country
  36. 5.7.1 South America IBS-C Drugs Market Size by Country: 2021 VS 2025 VS 2032
  37. 5.7.2 South America IBS-C Drugs Sales by Country (2021-2032)
  38. 5.7.3 South America IBS-C Drugs Revenue by Country (2021-2032)
  39. 5.7.4 Mexico
  40. 5.7.5 Brazil
  41. 5.7.6 Argentina
  42. 5.7.7 Colombia
  43. 5.8 Middle East and Africa IBS-C Drugs Market Facts & Figures by Country
  44. 5.8.1 Middle East and Africa IBS-C Drugs Market Size by Country: 2021 VS 2025 VS 2032
  45. 5.8.2 Middle East and Africa IBS-C Drugs Sales by Country (2021-2032)
  46. 5.8.3 Middle East and Africa IBS-C Drugs Revenue by Country (2021-2032)
  47. 5.8.4 Turkey
  48. 5.8.5 Saudi Arabia
  49. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global IBS-C Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global IBS-C Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global IBS-C Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global IBS-C Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global IBS-C Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global IBS-C Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global IBS-C Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global IBS-C Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global IBS-C Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global IBS-C Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global IBS-C Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global IBS-C Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global IBS-C Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global IBS-C Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 IBS-C Drugs Value Chain Analysis
  2. 8.1.1 IBS-C Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 IBS-C Drugs Production Mode & Process
  5. 8.2 IBS-C Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 IBS-C Drugs Distributors
  8. 8.2.3 IBS-C Drugs Customers
9 Global IBS-C Drugs Analyzing Market Dynamics
  1. 9.1 IBS-C Drugs Industry Trends
  2. 9.2 IBS-C Drugs Industry Drivers
  3. 9.3 IBS-C Drugs Industry Opportunities and Challenges
  4. 9.4 IBS-C Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst